Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BALANCED SALT vs METHOHEXITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.
Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.
Intraocular irrigation during ophthalmic surgery,Irrigation of wounds, body cavities, and tissues during surgical procedures,Replacement of extracellular fluid in hypovolemia (off-label)
Induction of anesthesia (FDA-approved),Maintenance of anesthesia (as an adjunct) (FDA-approved),Procedural sedation (off-label),Treatment of refractory status epilepticus (off-label)
Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.
Not applicable; components (sodium, chloride, potassium, calcium, magnesium, acetate, citrate) are endogenous and rapidly equilibrated; clinical context: no terminal elimination half-life as they are physiologic substances
Terminal elimination half-life is 1.6–4.8 hours (mean ~3.9 hours) in adults. Context: Rapid redistribution shortens clinical duration; elimination half-life is longer in elderly and hepatic impairment.
Not metabolized; components are directly excreted or incorporated into physiological pools. Excess ions are eliminated via renal excretion.
Primarily hepatic metabolism via CYP2B6 and other microsomal enzymes; undergoes oxidation and glucuronidation. Active metabolites are minimally important.
Renal: >95% of electrolytes and water eliminated unchanged via kidneys (glomerular filtration and tubular reabsorption dynamics); biliary/fecal: <5%
Renal: <1% unchanged; hepatic metabolism followed by renal excretion of metabolites accounts for >95% of elimination. Fecal: negligible (<1%).
Minimal to none; electrolytes are free in solution; no significant binding to plasma proteins (e.g., albumin, globulins)
85–90% bound to albumin.
Approximately 0.2 L/kg (extracellular fluid volume); clinically indicates distribution primarily into interstitial and intravascular spaces
2.0–3.0 L/kg; context: High Vd due to extensive tissue distribution, especially to adipose tissue.
Intravenous: 100%; ophthalmic: Not applicable (topical administration delivers directly to site, systemic absorption negligible)
Intramuscular: ~90–100%; Rectal: ~70–80%; Oral: not available (inactive due to first-pass metabolism).
No dose adjustment required for intraocular use. For IV use, caution in severe renal impairment (e GFR <30 m L/min) with monitoring for electrolyte imbalances; consider reducing infusion rate.
No specific dose adjustment required for GFR 30-89 m L/min. For GFR <30 m L/min or dialysis: use with caution; consider reduced dose due to potential prolonged effect.
No adjustment required for either route; balanced salt solution is not hepatically metabolized.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use alternative agent or reduce dose by 50% with careful titration.
Intraocular: as per surgeon's discretion. IV: weight-based, 10-20 m L/kg bolus then 2-5 m L/kg/hour continuous infusion for volume depletion.
Induction: 1-2 mg/kg IV bolus. Maintenance: 0.5-1 mg/kg IV bolus as needed. Maximum single dose: 100 mg.
No specific dose adjustment; monitor for fluid overload and electrolyte disturbances, especially in patients with cardiac or renal compromise.
Reduce initial dose by 25-50% (0.5-1 mg/kg IV) and titrate slowly due to increased sensitivity and prolonged recovery.
None.
Risk of respiratory depression and apnea; intravenous administration should be performed only by persons trained in the use of general anesthetics and able to maintain a patent airway and support ventilation. Continuous monitoring of respiratory function is required.
Hypersensitivity reactions may occur,Use with caution in patients with renal impairment due to risk of electrolyte overload,Monitor serum electrolytes and fluid balance during prolonged use,Do not use if solution is discolored or contains particulate matter
Respiratory depression and apnea,Hypotension and bradycardia,Injection site reactions (thrombophlebitis, necrosis, extravasation),Risk of emergence delirium and postoperative confusion,Laryngospasm and bronchospasm,Accumulation with repeated doses in patients with hepatic or renal impairment
Hypersensitivity to any component,Severe electrolyte disturbances (e.g., hyperkalemia, hypernatremia),Hepatic failure (relative contraindication due to fluid overload risk)
Hypersensitivity to methohexital or other barbiturates,Acute intermittent porphyria or porphyria variegata,Uncontrolled severe hypotension or shock,Status asthmaticus,Severe respiratory insufficiency,Known or suspected massive drug overdose
No known food interactions. Maintain normal hydration unless otherwise instructed.
No specific food interactions are documented for methohexital sodium. However, it is recommended to avoid heavy meals immediately before anesthesia to reduce risk of aspiration. Grapefruit juice may theoretically increase barbiturate levels by inhibiting CYP3A4, though clinical significance is unclear. Always follow pre-operative fasting instructions.
No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).
Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal studies show developmental toxicity at high doses. In the second and third trimesters, there is a risk of fetal depression and neonatal withdrawal if used chronically near term. Avoid in first trimester if possible; use only if clearly needed.
No known risk during breastfeeding; M/P ratio not available, but systemic absorption is minimal.
Methohexital enters breast milk in low amounts; the infant dose is estimated at <1% of maternal weight-adjusted dose. M/P ratio is approximately 0.5. Due to potential for neonatal sedation and the drug's short half-life, breastfeeding should be avoided for at least 4-6 hours after maternal administration.
No dose adjustments required during pregnancy due to negligible systemic absorption.
Pregnancy may alter pharmacokinetics: increased volume of distribution and clearance may require slightly higher initial doses for induction, but no specific dose adjustment is recommended; titrate to effect. Use lowest effective dose due to potential for fetal depression.
Use a sterile technique for intraocular irrigation. Avoid prolonged corneal exposure. Discard unused solution immediately. Monitor intraocular pressure post-procedure.
METHOHEXITAL SODIUM is an ultra-short-acting barbiturate used for induction of general anesthesia. It has a rapid onset (less than 30 seconds) and short duration (5-10 minutes) due to redistribution. It is highly protein-bound and should be used with caution in patients with hypoalbuminemia. Contraindicated in porphyria. Avoid extravasation as it is a tissue irritant. May cause apnea, laryngospasm, and hypotension. Dose reduction needed in elderly or debilitated patients.
Report any eye pain, redness, or vision changes immediately.,Do not touch the dropper tip to any surface.,Use as directed by your surgeon.,Discard bottle after single use.
This medication will cause you to lose consciousness quickly and is only given by a healthcare professional.,You will be closely monitored during and after administration.,You may experience drowsiness, dizziness, or confusion after waking up; do not drive or operate machinery for 24 hours.,Inform your doctor if you have any allergies, porphyria, or liver/kidney disease.,Avoid alcohol and other sedatives for at least 24 hours after receiving this medication.
No interactions on record
"The combination of methohexital, a barbiturate anesthetic, and mesoridazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression and respiratory depression due to synergistic pharmacodynamic effects on GABAergic and dopaminergic pathways. This interaction may result in enhanced sedation, hypotension, and increased risk of respiratory arrest, particularly during induction or maintenance of anesthesia. Patients with underlying respiratory or cardiovascular compromise are at heightened risk for severe adverse outcomes."
"Methohexital, a barbiturate anesthetic, induces cytochrome P450 (CYP) 3A4 enzyme activity, accelerating the hepatic metabolism of azelnidipine, a dihydropyridine calcium channel blocker. This results in reduced plasma concentrations and diminished antihypertensive efficacy of azelnidipine, potentially leading to inadequate blood pressure control during concurrent use."
"Concomitant use of Methohexital, a barbiturate anesthetic with central nervous system (CNS) depressant effects, and Guanfacine, an alpha-2 adrenergic agonist with sedative properties, can lead to additive CNS depression. This may result in enhanced sedation, respiratory depression, hypotension, and bradycardia. Patients may experience excessive drowsiness, impaired cognitive and motor function, and increased risk of falls or respiratory compromise, particularly during anesthesia induction or recovery."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BALANCED SALT vs METHOHEXITAL SODIUM, answered by our medical review team.
BALANCED SALT is a Ophthalmic Solution that works by Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.. METHOHEXITAL SODIUM is a Barbiturate Anesthetic that works by Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BALANCED SALT and METHOHEXITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BALANCED SALT is: Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.. The standard adult dose of METHOHEXITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BALANCED SALT and METHOHEXITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BALANCED SALT is classified as Category C. No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).. METHOHEXITAL SODIUM is classified as Category C. Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.